Anavex Life Sciences Corp (AVXL)

[nidan7500]

As an intellectual proposition...OK we get it, But REALLY?

Biogen also had recently given already nervous investors even more reasons to worry. At the Leerink Healthcare Conference in February, Biogen’s chief medical officer, Al Sandrock, said Biogen was adding 510 more patients to its clinical trial of aducanumab in Alzheimer’s disease. “We did see more variability on the primary endpoint than assumed when we did the initial sample size estimates,” he said. “So we decided to increase the sample size to maintain 90 percent power.”
This was widely perceived as meaning the company wasn’t getting the results it expected, so it was increasing the sample size. It caused shares to drop by 9.1 percent, the biggest intraday decline since June 2016.
Bloomberg noted, “The problem seems to have been that the tests were creating too much statistical noise, and not giving researchers a clear indication of whether or not the drug was helping patients.”

https://www.biospace.com/article/does-novartis-s-acquisition-of-avexis-spell-trouble-for-biogen-/?utm_source=Email_JS&utm_medium=Newsletter&utm_campaign=GP_20180411